This week, the overall grades of seven biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This week, SIGA Technologies, Inc. (SIGA) falls to a D (“sell”), worse than last week’s grade of C (“hold”). SIGA Technologies is a bio-defense company engaged in the discovery, development and commercialization of products for use in defense against biological warfare agents such as smallpox and arenaviruses. In Portfolio Grader’s specific subcategories of Earnings Revisions, Equity and Cash Flow, SIGA also gets an F. The stock price has fallen 5.4% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of SIGA stock.
This week, Trius Therapeutics, Inc.’s (TSRX) rating worsens to a D from the company’s C rating a week ago. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. For a full analysis of TSRX stock, visit Portfolio Grader.
Nanosphere, Inc. (NSPH) gets weaker ratings this week as last week’s C drops to a D. Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform. The stock gets F’s in Equity and Cash Flow. The stock price has fallen 15% over the past month. To get an in-depth look at NSPH, get Portfolio Grader’s complete analysis of NSPH stock.
Sunesis Pharmaceuticals, Inc. (SNSS) is having a tough week. The company’s rating falls from a C to a D. Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical Company which focuses on the discovery, development and commercialization of novel small molecule therapeutics for oncology. The stock also gets an F in Cash Flow. Share prices fell 9.8% over the past month. As of Feb. 5, 2014, 10% of outstanding Sunesis Pharmaceuticals, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of SNSS stock.
Oncolytics Biotech (ONCY) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Oncolytics Biotech discovers and develops pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at ONCY, get Portfolio Grader’s complete analysis of ONCY stock.
This week, Navidea Biopharmaceuticals, Inc. (NAVB) drops from a D to an F rating. Navidea Biopharmaceuticals is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer. The stock gets F’s in Equity and Cash Flow. As of Feb. 5, 2014, 13.4% of outstanding Navidea Biopharmaceuticals, Inc. shares were held short. For a full analysis of NAVB stock, visit Portfolio Grader.
The rating of Targacept, Inc. (TRGT) slips from a C to a D. Targacept is an a biopharmaceutical company engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting neuronal nicotinic acetylcholine receptors. The stock gets F’s in Equity, Cash Flow and Sales Growth. To get an in-depth look at TRGT, get Portfolio Grader’s complete analysis of TRGT stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
